It is very uncertain whether human activated protein C changes mortality from any cause (15‐day and 30‐day in‐hospital) compared with heparin (very low certainty).
It is very uncertain whether human activated protein C changes adverse events compared with heparin (very low certainty).
It is very uncertain whether human activated protein C changes bleeding compared with heparin (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Human recombinant activated protein C showed no clear difference in 28‐Day all‐cause mortality (adult and paediatric patients) compared with placebo (moderate certainty).
Human recombinant activated protein C showed no clear difference in in‐hospital mortality (adult and paediatric patients) compared with placebo (moderate certainty).
Human recombinant activated protein C probably leads to higher serious bleeding events in adult and paediatric patients (days 0 to… compared with placebo (moderate certainty).
Human recombinant activated protein C showed no clear difference in serious adverse events (adult and paediatric patients) compared with placebo (moderate certainty).